Analytical Method For Increasing Susceptibility Of Molecular Targeted Therapy In Hepatocellular Carcinoma


The present invention provides an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment. It has been found by the present invention that FGFR1 has relationship with susceptibility to sorafenib treatment. Therefore, the analysis on the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFRβ, c-KIT, c-RAF, EGFR, and/or mTOR) makes it possible to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.

Download PDF
Document Preview
Document History
  • Publication: Oct 30, 2014
  • Application: Apr 16, 2014
    WO KR 2014003281 W
  • Priority: Apr 25, 2013
    KR KR 20130046279 A

Download Citation

Sign in to the Lens